Nifty Top Losers: Cipla, Sun Pharma, Infosys stocks drag on Nifty 50 in today's trading

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Several stocks experienced declines in Wednesday's trading session, with Cipla, Sun Pharma, and Infosys among the top losers on the Nifty 50. At 10:30 am, Cipla's stock was trading at Rs 1,479.80, reflecting a 1.33% decrease from its previous close.

Sun Pharma's stock was trading at Rs 1,611.60, down by 1.26% from its previous close, while Infosys was trading at Rs 1,442.60, a 1.21% decline from its previous close. Other stocks that experienced notable declines include Wipro, which fell by 1.2% to Rs 242.95, and Tech Mahindra, which decreased by 1.19% to Rs 1,467.70.

Cipla Financial Performance:

Cipla's consolidated financial performance shows consistent revenue and net profit growth over the past few years. The company's revenue for the year ending March 2025 was Rs 27,547.62 Crore, compared to Rs 25,774.09 Crore for the year ending March 2024, representing a 6.88% increase. The net profit for the same period increased significantly, from Rs 4,155.31 Crore in 2024 to Rs 5,291.05 Crore in 2025, a 27.33% rise.

The company's quarterly performance also reflects steady growth. For the quarter ending June 2025, Cipla's revenue stood at Rs 6,957.47 Crore, compared to Rs 6,693.94 Crore in June 2024. The net profit for the same period was Rs 1,292.05 Crore, up from Rs 1,176.29 Crore.

Key financial ratios for Cipla indicate a strong financial position. The company reported a debt-to-equity ratio of 0.00 as of the year ending March 2025. Return on Equity (ROE) was 16.90% for the year ending March 2025, compared to 15.43% for the previous year. The P/E ratio as of March 2025 was 22.09, while the P/B ratio was 3.73.

Cipla - Consolidated Yearly Figures (in Rs. Crore)

Sun Pharma's consolidated financial performance reveals substantial revenue and net profit growth over the past several years. The company's revenue for the year ending March 2025 reached Rs 52,578.44 Crore, a notable increase from Rs 48,496.85 Crore in the year ending March 2024, marking an 8.41% rise. Concurrently, the net profit surged from Rs 9,648.44 Crore in 2024 to Rs 10,980.10 Crore in 2025, reflecting a 13.80% growth.

The quarterly performance also indicates consistent growth. For the quarter ending June 2025, Sun Pharma reported revenue of Rs 13,851.40 Crore, compared to Rs 12,652.75 Crore in June 2024. The net profit for the same period was Rs 2,302.62 Crore, up from Rs 2,871.25 Crore.

Key financial ratios for Sun Pharma demonstrate a stable financial position. The company's debt-to-equity ratio stood at 0.03 as of the year ending March 2025. The Return on Equity (ROE) was 15.13% for the year ending March 2025, consistent with the previous year. The P/E ratio as of March 2025 was 38.04, while the P/B ratio was 5.77.

Sun Pharma - Consolidated Yearly Figures (in Rs. Crore)

Infosys' consolidated financial performance indicates consistent revenue growth but fluctuating net profit over the past few years. The company's revenue for the year ending March 2025 was Rs 162,990.00 Crore, compared to Rs 153,670.00 Crore for the year ending March 2024, representing a 6.06% increase. However, the net profit showed a slight increase, from Rs 26,248.00 Crore in 2024 to Rs 26,750.00 Crore in 2025, a 1.91% rise.

The company's quarterly performance also reflects steady growth. For the quarter ending June 2025, Infosys' revenue stood at Rs 42,279.00 Crore, compared to Rs 39,315.00 Crore in June 2024. The net profit for the same period was Rs 6,924.00 Crore, up from Rs 6,374.00 Crore.

Key financial ratios for Infosys demonstrate a strong financial position. The company reported a debt-to-equity ratio of 0.00 as of the year ending March 2025. Return on Equity (ROE) was 27.87% for the year ending March 2025, compared to 29.77% for the previous year. The P/E ratio as of March 2025 was 24.35, while the P/B ratio was 6.80.

Infosys - Consolidated Yearly Figures (in Rs. Crore)

Wipro's consolidated financial performance presents a mixed picture with revenue showing modest growth and net profit fluctuating over the past several years. The company's revenue for the year ending March 2025 was Rs 52,988.30 Crore, compared to Rs 51,995.50 Crore for the year ending March 2024, reflecting a 1.91% increase. However, the net profit increased significantly from Rs 2,386.30 Crore in 2024 to Rs 4,244.40 Crore in 2025, marking a substantial rise of 77.86%.

The quarterly performance also indicates some variability. For the quarter ending June 2025, Wipro's revenue stood at Rs 13,351.20 Crore, compared to Rs 13,005.50 Crore in June 2024. The net profit for the same period was Rs 1,128.30 Crore, up from Rs 862.20 Crore.

Key financial ratios for Wipro reveal certain trends. The company reported a debt-to-equity ratio of 0.02 as of the year ending March 2025. Return on Equity (ROE) was 15.53% for the year ending March 2025, compared to 8.84% for the previous year. The P/E ratio as of March 2025 was 29.55, while the P/B ratio was 4.59.

Wipro - Consolidated Yearly Figures (in Rs. Crore)

Tech Mahindra's consolidated financial performance shows stable revenue and fluctuating net profit over the past few years. The company's revenue for the year ending March 2025 was Rs 52,988.30 Crore, compared to Rs 51,995.50 Crore for the year ending March 2024, representing a 1.91% increase. The net profit increased significantly, from Rs 2,386.30 Crore in 2024 to Rs 4,244.40 Crore in 2025, a 77.86% rise.

The company's quarterly performance also reflects steady growth. For the quarter ending June 2025, Tech Mahindra's revenue stood at Rs 13,351.20 Crore, compared to Rs 13,005.50 Crore in June 2024. The net profit for the same period was Rs 1,128.30 Crore, up from Rs 862.20 Crore.

Key financial ratios for Tech Mahindra indicate a strong financial position. The company reported a debt-to-equity ratio of 0.02 as of the year ending March 2025. Return on Equity (ROE) was 15.53% for the year ending March 2025, compared to 8.84% for the previous year. The P/E ratio as of March 2025 was 29.55, while the P/B ratio was 4.59.

Tech Mahindra - Consolidated Yearly Figures (in Rs. Crore)

Cipla

Cipla Ltd has several corporate announcements, including updates on USFDA inspections at its manufacturing facility in Bommasandra, Bengaluru, and clarifications on news items related to pharma stocks. Additionally, the Exchange has sought clarification from Cipla Ltd regarding news about pharma stocks slumping due to letters from Trump seeking lower prices.

The company announced a final dividend of Rs 13.00 per share (650%) and a special dividend of Rs 3.00 per share (150%), both effective from June 27, 2025.

Cipla has a history of bonus issues, including a 3:2 bonus ratio on February 11, 2006, and a 2:1 bonus ratio on October 7, 1999. The company also had a split with old FV of 10 and new FV of 2 on May 11, 2004.

Sun Pharma

Sun Pharma has made announcements regarding analyst/investor meetings and disclosures under SEBI regulations.The company announced a final dividend of Rs 5.50 per share (550%) effective from July 7, 2025 and an interim dividend of Rs 10.50 per share (1050%) effective from February 6, 2025.

Infosys

Infosys has been actively involved in investor conferences and has made disclosures under Regulation 30 of the SEBI LODR Regulations.

Infosys announced a final dividend of Rs 22.00 per share (440%) effective from May 30, 2025, and an interim dividend of Rs 21.00 per share (420%) effective October 29, 2024.

Wipro

Wipro has announced the allotment of ESOP/ESPS and has published newspaper advertisements related to regulatory compliance.

Wipro announced an interim dividend of Rs 5.00 per share (250%) effective from July 28, 2025, and another interim dividend of Rs 6.00 per share (300%) effective from January 28, 2025.The company also issued a bonus share with 1:1 ratio on December 3, 2024.

In conclusion, several Nifty 50 stocks, including Cipla, Sun Pharma and Infosys, experienced declines in Wednesday's trading session.